ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2026-1-144-151ssmu-6410Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEW AND LECTURESИнфантильная гемангиома: современный взгляд на патогенез и лечениеInfantile hemangioma: modern perspectives on pathogenesis and treatmenthttps://orcid.org/0009-0004-1942-7773БуковецкаяМ. С.BukovetskayaM. S.

Буковецкая Мария Сергеевна – врач-гематолог

Россия, 634009, г. Томск, ул. Карла Маркса, 44

44 Karl Marx St., 634009 Tomsk, Russian Federation

buk.ms@mail.ruhttps://orcid.org/0000-0002-2234-5355КамалтыноваЕ. М.KamaltynovaE. M.

Камалтынова Елена Михайловна – д-р мед. наук, зам. гл. врача по медицинским вопросам; профессор кафедры факультетской педиатрии с курсом детских болезней лечебного факультета, гл. внештатный детский специалист по профилактической работе СФО

Россия, 634009, г. Томск, ул. Карла Маркса, 44Россия, 634050, г. Томск, Московский тракт, 2

44 Karl Marx St., 634009 Tomsk, Russian Federation2 Moskovsky trakt, 634050 Tomsk, Russian Federation

eleant21@yandex.ruОбластная детская больница (ОДБ)РоссияRegional Children’s HospitalRussian FederationОбластная детская больница (ОДБ); Сибирский государственный медицинский университет (СибГМУ)РоссияRegional Children’s Hospital; Siberian State Medical UniversityRussian Federation202613042026251144151Copyright © Буковецкая М.С., Камалтынова Е.М., 20262026Буковецкая М.С., Камалтынова Е.М.Bukovetskaya M.S., Kamaltynova E.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/6410

Инфантильная гемангиома (ИГ) – значимая и распространенная проблема междисциплинарного характера в детской популяции. Этиология данного заболевания до конца не известна. Существует несколько гипотез возникновения ИГ: плацентарная, в результате генетической мутации и воздействия внешних факторов. Подходы к лечению инфантильных гемангиом разнообразны и включают системную фармакотерапию, местное и хирургическое лечение. Каждый из них обладает как достоинствами, так и ограничениями, что делает невозможным использование одного из методов в качестве универсального для всех пациентов. Препаратом первой линии в настоящее время признан β-адреноблокатор пропранолол.Авторы лекции представили литературный обзор современных подходов к выбору лечения инфантильных гемангиом, а также предикторы эффективности применения пропранолола и его возможный механизм действия.

Infantile hemangioma (IH) is a significant and common interdisciplinary issue in the pediatric population. The etiology of this condition is not fully understood. Several hypotheses exist regarding the origin of IH: the placental hypothesis, genetic mutations, and the influence of external factors. Treatment approaches for IH are diverse and include systemic pharmacotherapy, local treatment, and surgical intervention. Each of these methods has both advantages and limitations, making it impossible to use any single approach as a universal solution for all patients. The beta-blocker propranolol is currently recognized as the first-line medication. The authors of the lecture presented a literature review of modern approaches to selecting treatment for IH, as well as predictors of propranolol efficacy and its possible mechanism of action.

гемангиомамальформациядетипропранололhemangiomamalformationchildrenpropranololReferencesDrolet B.A., Frommelt P.C., Chamlin S.L., Haggstrom A.N., Bauman N.M., Chiu Y.E. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–140. DOI: 10.1542/peds.2012-1691.Drolet B.A., Frommelt P.C., Chamlin S.L., Haggstrom A.N., Bauman N.M., Chiu Y.E. et al. Initiation and use of propranolol for infantile hemangioma: report of a consensus conference. Pediatrics. 2013;131(1):128–140. DOI: 10.1542/peds.2012-1691.Хачатрян Л.А., Клецкая И.С. Просто о сложном: инфантильная гемангиома. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021;20(1):192–206.Хачатрян Л.А., Клецкая И.С. Просто о сложном: инфантильная гемангиома. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021;20(1):192–206.Rodríguez Bandera A.I., Sebaratnam D.F., Wargon O., Wong L.-C.F. Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment. Journal of the American Academy of Dermatology. 2021;85(6):1379–1392. DOI: 10.1016/j.jaad.2021.08.019.Rodríguez Bandera A.I., Sebaratnam D.F., Wargon O., Wong L.-C.F. Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment. Journal of the American Academy of Dermatology. 2021;85(6):1379–1392. DOI: 10.1016/j.jaad.2021.08.019.Chang L.C., Haggstrom A.N., Drolet B.A., Baselga E., Chamlin S.L., Garzon M.C. et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360–367. DOI: 10.1542/peds.2007-2767.Chang L.C., Haggstrom A.N., Drolet B.A., Baselga E., Chamlin S.L., Garzon M.C. et al. Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008;122(2):360–367. DOI: 10.1542/peds.2007-2767.Holm A., Mulliken J. B., Bischoff J. Infantile hemangioma: the common and enigmatic vascular tumor. The Journal of Clinical Investigation. 2024;134(8):e172836. DOI: 10.1172/JCI172836.Holm A., Mulliken J. B., Bischoff J. Infantile hemangioma: the common and enigmatic vascular tumor. The Journal of Clinical Investigation. 2024;134(8):e172836. DOI: 10.1172/JCI172836.Wassef M., Blei F., Adams D., Alomari A., Baselga E., Berenstein A. et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015;136(1):e203–e214. DOI: 10.1542/peds.2014-3673.Wassef M., Blei F., Adams D., Alomari A., Baselga E., Berenstein A. et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015;136(1):e203–e214. DOI: 10.1542/peds.2014-3673.Хачатрян Л.А., Щербаков А.П., Чиквина И.И., Николаева Д.М. Новые подходы к решению старой проблемы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022;21(1):122–135. DOI: 10.24287/1726-1708-2022-21-1-122-135.Хачатрян Л.А., Щербаков А.П., Чиквина И.И., Николаева Д.М. Новые подходы к решению старой проблемы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2022;21(1):122–135. DOI: 10.24287/1726-1708-2022-21-1-122-135.Schwartz R.A., Sidor M.I., Musumeci M.L., Lin R.L., Micali G. Infantile haemangiomas: a challenge in paediatric dermatology. Journal of the European Academy of Dermatology and Venereology. 2010;24(6):631–638. DOI: 10.1111/j.1468-3083.2010.03650.x.Schwartz R.A., Sidor M.I., Musumeci M.L., Lin R.L., Micali G. Infantile haemangiomas: a challenge in paediatric dermatology. Journal of the European Academy of Dermatology and Venereology. 2010;24(6):631–638. DOI: 10.1111/j.1468-3083.2010.03650.x.Léauté-Labrèze C., Harper J.I., Hoeger P.H. Infantile haemangioma. The Lancet. 2017;390(10089):85–94. DOI: 10.1016/S0140-6736(16)00645-0.Léauté-Labrèze C., Harper J.I., Hoeger P.H. Infantile haemangioma. The Lancet. 2017;390(10089):85–94. DOI: 10.1016/S0140-6736(16)00645-0.Siegel D.H. PHACE syndrome: Infantile hemangiomas associated with multiple congenital anomalies: Clues to the cause. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2018;178C(3):407–413. DOI: 10.1002/ajmg.c.31648.Siegel D.H. PHACE syndrome: Infantile hemangiomas associated with multiple congenital anomalies: Clues to the cause. American Journal of Medical Genetics Part C: Seminars in Medical Genetics. 2018;178C(3):407–413. DOI: 10.1002/ajmg.c.31648.Iacobas I., Burrows P.E., Frieden I.J., Liang M.G., Mulliken J.B., Mancini A.J. et al. LUMBAR: Association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. The Journal of Pediatrics. 2010;157(5):795–801.e1–е7. DOI: 10.1016/j.jpeds.2010.05.027.Iacobas I., Burrows P.E., Frieden I.J., Liang M.G., Mulliken J.B., Mancini A.J. et al. LUMBAR: Association between cutaneous infantile hemangiomas of the lower body and regional congenital anomalies. The Journal of Pediatrics. 2010;157(5):795–801.e1–е7. DOI: 10.1016/j.jpeds.2010.05.027.Хачатрян Л.А., Николаева Д.М., Щербаков А.П. Когда болезнь выходит за пределы кожи – изменения на коже могут быть признаком системного заболевания. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(3):95–104. DOI: 10.24287/1726-1708-2020-19-3-95-104.Хачатрян Л.А., Николаева Д.М., Щербаков А.П. Когда болезнь выходит за пределы кожи – изменения на коже могут быть признаком системного заболевания. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(3):95–104. DOI: 10.24287/1726-1708-2020-19-3-95-104.Baselga E., Roe E., Coulie J., Muñoz F.Z., Boon L.M., McCuaig C.M. et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatology. 2016;152(11):1239–1243. DOI: 10.1001/jamadermatol.2016.2905.Baselga E., Roe E., Coulie J., Muñoz F.Z., Boon L.M., McCuaig C.M. et al. Risk factors for degree and type of sequelae after involution of untreated hemangiomas of infancy. JAMA Dermatology. 2016;152(11):1239–1243. DOI: 10.1001/jamadermatol.2016.2905.Itinteang T., Tan S.T., Guthrie S., Tan C.E.S., McIntyre B.C., Brasch H.D., Day D.J. A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma. Journal of Clinical Pathology. 2011;64(10):870–874. DOI: 10.1136/jclinpath-2011-200191.Itinteang T., Tan S.T., Guthrie S., Tan C.E.S., McIntyre B.C., Brasch H.D., Day D.J. A placental chorionic villous mesenchymal core cellular origin for infantile haemangioma. Journal of Clinical Pathology. 2011;64(10):870–874. DOI: 10.1136/jclinpath-2011-200191.Sun Z.Y., Yi C.G., Zhao H., Yin G.Q., Gao M., Liu Y.B. et al. Infantile hemangioma is originated from placental trophoblast, fact or fiction? Medical Hypotheses. 2008;71(3):444–448.Sun Z.Y., Yi C.G., Zhao H., Yin G.Q., Gao M., Liu Y.B. et al. Infantile hemangioma is originated from placental trophoblast, fact or fiction? Medical Hypotheses. 2008;71(3):444–448.Bauland C.G., van Steensel M.A.M., Steijlen P.M. et al. Hemangioma in the newborn: increased incidence after chorionic villus sampling. Diagnosis. 2010;30(10):913–917.Bauland C.G., van Steensel M.A.M., Steijlen P.M. et al. Hemangioma in the newborn: increased incidence after chorionic villus sampling. Diagnosis. 2010;30(10):913–917.Moisan F., Oucherif S., Kaulanjan-Checkmodine P., Prey S., Rousseau B., Bonneu M. et al. Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(7):e2018690118. DOI: 10.1073/pnas.2018690118.Moisan F., Oucherif S., Kaulanjan-Checkmodine P., Prey S., Rousseau B., Bonneu M. et al. Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(7):e2018690118. DOI: 10.1073/pnas.2018690118.Harbi S., Wang R., Gregory M., Hanson N., Kobylarz K., Ryan K. et al. Infantile hemangioma originates from a dysregulated but not fully transformed multipotent stem cell. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(7):1592–1597. DOI: 10.1073/pnas.1516258113.Harbi S., Wang R., Gregory M., Hanson N., Kobylarz K., Ryan K. et al. Infantile hemangioma originates from a dysregulated but not fully transformed multipotent stem cell. Proceedings of the National Academy of Sciences of the United States of America. 2016;113(7):1592–1597. DOI: 10.1073/pnas.1516258113.Castrén E., Salminen P., Vikkula M., Pitkäranta A., Klockars T. Inheritance patterns of infantile hemangioma. Pediatrics. 2016;138(5):e20161623. DOI: 10.1542/peds.2016-1623.Castrén E., Salminen P., Vikkula M., Pitkäranta A., Klockars T. Inheritance patterns of infantile hemangioma. Pediatrics. 2016;138(5):e20161623. DOI: 10.1542/peds.2016-1623.Oszajca K., Szemraj J., Wyrzykowski D., Chrzanowska B., Salamon A., Przewratil P. Single-nucleotide polymorphisms of VEGF-A and VEGFR-2 genes and risk of infantile hemangioma. International Journal of Dermatology. 2018;57(10):1201–1207. DOI: 10.1111/ijd.14127.Oszajca K., Szemraj J., Wyrzykowski D., Chrzanowska B., Salamon A., Przewratil P. Single-nucleotide polymorphisms of VEGF-A and VEGFR-2 genes and risk of infantile hemangioma. International Journal of Dermatology. 2018;57(10):1201–1207. DOI: 10.1111/ijd.14127.Chen Q., Ying H., Yu Z., Chang L., Chen Z., Chen J. et al. Apelin receptor as a specific marker and promising therapeutic target for infantile hemangioma. Journal of Investigative Dermatology. 2023;143(4):566–577.e12. DOI: 10.1016/j.jid.2022.09.657.Chen Q., Ying H., Yu Z., Chang L., Chen Z., Chen J. et al. Apelin receptor as a specific marker and promising therapeutic target for infantile hemangioma. Journal of Investigative Dermatology. 2023;143(4):566–577.e12. DOI: 10.1016/j.jid.2022.09.657.Xiang S., Gong X., Qiu T., Zhou J., Yang K., Lan Y. Insights into the mechanisms of angiogenesis in infantile hemangioma. Biomedicine & Pharmacotherapy. 2024;178:116345.Xiang S., Gong X., Qiu T., Zhou J., Yang K., Lan Y. Insights into the mechanisms of angiogenesis in infantile hemangioma. Biomedicine & Pharmacotherapy. 2024;178:116345.Wu H., Ji Y., Zheng J. Editorial: Advances in the medical management of infantile hemangioma. Frontiers in Oncology. 2023;13:1229197. DOI: 10.3389/fonc.2023.1229197.Wu H., Ji Y., Zheng J. Editorial: Advances in the medical management of infantile hemangioma. Frontiers in Oncology. 2023;13:1229197. DOI: 10.3389/fonc.2023.1229197.De Jong S., Itinteang T., Withers A.H.J., Davis P.F., Tan S.T. Does hypoxia play a role in infantile hemangioma? Archives of Dermatological Research. 2016;308(4):219–227. DOI: 10.1007/s00403-016-1635-x.De Jong S., Itinteang T., Withers A.H.J., Davis P.F., Tan S.T. Does hypoxia play a role in infantile hemangioma? Archives of Dermatological Research. 2016;308(4):219–227. DOI: 10.1007/s00403-016-1635-x.Drolet B.A., Frieden I.J. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Archives of Dermatology. 2010;146(11):1295–1299. DOI: 10.1001/archdermatol.2010.1295-1299.Drolet B.A., Frieden I.J. Characteristics of infantile hemangiomas as clues to pathogenesis: does hypoxia connect the dots? Archives of Dermatology. 2010;146(11):1295–1299. DOI: 10.1001/archdermatol.2010.1295-1299.Lo K., Mihm M., Fay A. Current theories on the pathogenesis of infantile hemangioma. Seminars in Ophthalmology. 2009;24(3):172–177. DOI: 10.1080/08820530902805438.Lo K., Mihm M., Fay A. Current theories on the pathogenesis of infantile hemangioma. Seminars in Ophthalmology. 2009;24(3):172–177. DOI: 10.1080/08820530902805438.Hyland R.M., Komlósi K., Alleman B.W., Tolnai M., Wood L.M., Bell E.F., Ertl T. Infantile hemangiomas and retinopathy of prematurity: clues to the regulation of vasculogenesis. European Journal of Pediatrics. 2014;173(6):723–728.Hyland R.M., Komlósi K., Alleman B.W., Tolnai M., Wood L.M., Bell E.F., Ertl T. Infantile hemangiomas and retinopathy of prematurity: clues to the regulation of vasculogenesis. European Journal of Pediatrics. 2014;173(6):723–728.Praveen V., Vidavalur R., Rosenkrantz T.S., Hussain N. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics. 2009;123(3):e484–e489. DOI: 10.1542/peds.2008-2278.Praveen V., Vidavalur R., Rosenkrantz T.S., Hussain N. Infantile hemangiomas and retinopathy of prematurity: possible association. Pediatrics. 2009;123(3):e484–e489. DOI: 10.1542/peds.2008-2278.Kleinman M.E., Greives M.R., Churgin S.S., Blechman K.M., Chang E.I., Ceradini D.J. et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(12):2664–2670.Kleinman M.E., Greives M.R., Churgin S.S., Blechman K.M., Chang E.I., Ceradini D.J. et al. Hypoxia-induced mediators of stem/progenitor cell trafficking are increased in children with hemangioma. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(12):2664–2670.Zhang L., Wu H.W., Yuan W., Zheng J.W. Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma. Cancer Management and Research. 2017;9:279–286. DOI: 10.2147/CMAR.S138687.Zhang L., Wu H.W., Yuan W., Zheng J.W. Estrogen-mediated hemangioma-derived stem cells through estrogen receptor-α for infantile hemangioma. Cancer Management and Research. 2017;9:279–286. DOI: 10.2147/CMAR.S138687.Przewratil P., Sitkiewicz A., Andrzejewska E. Serum levels of basic fibroblastic growth factor (bFGF) in children with vascular anomalies: Another insight into endothelial growth. Clinical Biochemistry. 2010;43(10–11):863–867. DOI: 10.1016/j.clinbiochem.2010.03.010.Przewratil P., Sitkiewicz A., Andrzejewska E. Serum levels of basic fibroblastic growth factor (bFGF) in children with vascular anomalies: Another insight into endothelial growth. Clinical Biochemistry. 2010;43(10–11):863–867. DOI: 10.1016/j.clinbiochem.2010.03.010.Macca L., Altavilla D., Di Bartolomeo L., Irrera N., Borgia F., Li Pomi F. et al. Update on treatment of infantile hemangiomas: What’s new in the last five years? Frontiers in Pharmacology. 2022;13:879602. DOI: 10.3389/fphar.2022.879602.Macca L., Altavilla D., Di Bartolomeo L., Irrera N., Borgia F., Li Pomi F. et al. Update on treatment of infantile hemangiomas: What’s new in the last five years? Frontiers in Pharmacology. 2022;13:879602. DOI: 10.3389/fphar.2022.879602.Хачатрян Л.А., Чиквина И.И., Клецкая И.С. В поисках редкой болезни: врожденные гемангиомы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021;20(1):145–155. DOI: 10.24287/1726-1708-2021-20-1-145-155.Хачатрян Л.А., Чиквина И.И., Клецкая И.С. В поисках редкой болезни: врожденные гемангиомы. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021;20(1):145–155. DOI: 10.24287/1726-1708-2021-20-1-145-155.Khan M., Boyce A., Prieto-Merino A., Wedgeworth E., Flohr C. The role of topical Timolol in the treatment of infantile hemangiomas: A systematic review and meta-analysis. Acta Dermato-Venereologica. 2017;97(10):1167–1171. DOI: 10.2340/00015555-2725.Khan M., Boyce A., Prieto-Merino A., Wedgeworth E., Flohr C. The role of topical Timolol in the treatment of infantile hemangiomas: A systematic review and meta-analysis. Acta Dermato-Venereologica. 2017;97(10):1167–1171. DOI: 10.2340/00015555-2725.Price A., Rai S., McLeod R.W.J., Birchall J.C., Elhassan H.A. Topical propranolol for infantile haemangiomas: a systematic review. Journal of the European Academy of Dermatology and Venereology. 2018;32(12):2083–2089. DOI: 10.1111/jdv.14963.Price A., Rai S., McLeod R.W.J., Birchall J.C., Elhassan H.A. Topical propranolol for infantile haemangiomas: a systematic review. Journal of the European Academy of Dermatology and Venereology. 2018;32(12):2083–2089. DOI: 10.1111/jdv.14963.Muñoz-Garza F.Z., Ríos M., Roé-Crespo E., BernabeuWittel J., Montserrat-García M.T., Puig L. et al. Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage. JAMA Dermatology. 2021;157(5):583–587. DOI: 10.1001/jamadermatol.2021.0469.Muñoz-Garza F.Z., Ríos M., Roé-Crespo E., BernabeuWittel J., Montserrat-García M.T., Puig L. et al. Efficacy and safety of topical timolol for the treatment of infantile hemangioma in the early proliferative stage. JAMA Dermatology. 2021;157(5):583–587. DOI: 10.1001/jamadermatol.2021.0469.Regina G., Impedovo G., Angiletta D. et al. A new strategy for treatment of a congenital arteriovenous fistula of the neck: Case report. European Journal of Vascular and Endovascular Surgery. 2006;32:107–109.Regina G., Impedovo G., Angiletta D. et al. A new strategy for treatment of a congenital arteriovenous fistula of the neck: Case report. European Journal of Vascular and Endovascular Surgery. 2006;32:107–109.Хачатрян Л.А., Николаева Д.М. Современная терапия инфантильных гемангиом. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021;20(2):156–167.Хачатрян Л.А., Николаева Д.М. Современная терапия инфантильных гемангиом. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2021;20(2):156–167.David L.R., Malek M.M., Argenta L.C. Efficacy of pulse dye laser therapy for the treatment of ulcerated haemangiomas: A review of 78 patients. British Journal of Plastic Surgery. 2003;56(4):317–327.David L.R., Malek M.M., Argenta L.C. Efficacy of pulse dye laser therapy for the treatment of ulcerated haemangiomas: A review of 78 patients. British Journal of Plastic Surgery. 2003;56(4):317–327.Sajan J.A., Tibesar R., Jabbour N. et al. Assessment of pulseddye laser therapy for pediatric cutaneous vascular anomalies. JAMA Facial Plastic Surgery. 2013;15(6):434–438. DOI: 10.1001/jamafacial.2013.257.Sajan J.A., Tibesar R., Jabbour N. et al. Assessment of pulseddye laser therapy for pediatric cutaneous vascular anomalies. JAMA Facial Plastic Surgery. 2013;15(6):434–438. DOI: 10.1001/jamafacial.2013.257.Wedgeworth E., Glover M., Irvine A.D., Neri I., Baselga E. Clayton T.H. et al. Propranolol in the treatment of infantile haemangiomas: Lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. British Journal of Dermatology. 2016;174(3):594–601. DOI: 10.1111/bjd.14233.Wedgeworth E., Glover M., Irvine A.D., Neri I., Baselga E. Clayton T.H. et al. Propranolol in the treatment of infantile haemangiomas: Lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) Taskforce survey. British Journal of Dermatology. 2016;174(3):594–601. DOI: 10.1111/bjd.14233.Котлукова Н.П., Белышева Т.С., Шац Л.И., Фоченкова В.А., Чавпецова Э.Д., Белогурова М.Б. и др. Возможности медикаментозного лечения инфантильных гемангиом в России. Российский журнал детской гематологии и онкологии (РЖДГиО). 2022;9(2):22–28.Котлукова Н.П., Белышева Т.С., Шац Л.И., Фоченкова В.А., Чавпецова Э.Д., Белогурова М.Б. и др. Возможности медикаментозного лечения инфантильных гемангиом в России. Российский журнал детской гематологии и онкологии (РЖДГиО). 2022;9(2):22–28.Hoeger P.H., Harper J.I., Baselga E., Bonnet D., Boon L.M., Ciofi Degli Atti M. et al. Treatment of infantile haemangiomas: recommendations of a European expert group. European Journal of Pediatrics. 2015;174(7):855–865. DOI: 10.1007/s00431-015-2570-0.Hoeger P.H., Harper J.I., Baselga E., Bonnet D., Boon L.M., Ciofi Degli Atti M. et al. Treatment of infantile haemangiomas: recommendations of a European expert group. European Journal of Pediatrics. 2015;174(7):855–865. DOI: 10.1007/s00431-015-2570-0.Caussé S., Aubert H., Saint-Jean M., Puzenat E., Bursztejn A.-C., Eschard C. et al. Propranolol-resistant infantile haemangiomas. British Journal of Dermatology. 2013;169(1):125–129.Caussé S., Aubert H., Saint-Jean M., Puzenat E., Bursztejn A.-C., Eschard C. et al. Propranolol-resistant infantile haemangiomas. British Journal of Dermatology. 2013;169(1):125–129.Vlastarakos P.V., Papacharalampous G.X., Chrysostomou M., Tavoulari E.F., Delidis A., Protopapas D. et al. Propranolol is an effective treatment for airway haemangiomas: a critical analysis and meta-analysis of published interventional studies. Acta Otorhinolaryngologica Italica. 2012;32(4):213–221.Vlastarakos P.V., Papacharalampous G.X., Chrysostomou M., Tavoulari E.F., Delidis A., Protopapas D. et al. Propranolol is an effective treatment for airway haemangiomas: a critical analysis and meta-analysis of published interventional studies. Acta Otorhinolaryngologica Italica. 2012;32(4):213–221.Ye Y., Zhong H., Dou L., Song W., Dong C., Lu W. et al. Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. Pediatric Research. 2022;92(2):424–429. DOI: 10.1038/s41390-021-01683-4.Ye Y., Zhong H., Dou L., Song W., Dong C., Lu W. et al. Propranolol inhibits the angiogenic capacity of hemangioma endothelia via blocking β-adrenoceptor in mast cell. Pediatric Research. 2022;92(2):424–429. DOI: 10.1038/s41390-021-01683-4.Lorusso B., Cerasoli G., Falco A., Frati C., Graiani G., Madeddu D. et al. Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro. Vascular Pharmacology. 2022;146:107110. DOI: 10.1016/j.vph.2022.107110.Lorusso B., Cerasoli G., Falco A., Frati C., Graiani G., Madeddu D. et al. Β-blockers activate autophagy on infantile hemangioma-derived endothelial cells in vitro. Vascular Pharmacology. 2022;146:107110. DOI: 10.1016/j.vph.2022.107110.Makkeyah S., Elseedawy M., Abdel-Kader H., Mokhtar G., Ragab I. Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma. Pediatric Hematology and Oncology. 2022;39(3):215–224. DOI: 10.1080/08880018.2021.1961956.Makkeyah S., Elseedawy M., Abdel-Kader H., Mokhtar G., Ragab I. Vascular endothelial growth factor response with propranolol therapy in patients with infantile hemangioma. Pediatric Hematology and Oncology. 2022;39(3):215–224. DOI: 10.1080/08880018.2021.1961956.Yang K., Li X., Qiu T., Zhou J., Gong X., Lan Y. et al. Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells. Clinical and Applied Thrombosis/Hemostasis. 2018;24:663–668.Yang K., Li X., Qiu T., Zhou J., Gong X., Lan Y. et al. Effects of propranolol on glucose metabolism in hemangioma-derived endothelial cells. Clinical and Applied Thrombosis/Hemostasis. 2018;24:663–668.Rešić A., Benco Kordić N., Obuljen J., Bašković M. Importance of determining vascular endothelial growth factor serum levels in children with infantile hemangioma. Medicina (Kaunas). 2023;59(11):1914. DOI: 10.3390/medicina59111914.Rešić A., Benco Kordić N., Obuljen J., Bašković M. Importance of determining vascular endothelial growth factor serum levels in children with infantile hemangioma. Medicina (Kaunas). 2023;59(11):1914. DOI: 10.3390/medicina59111914.Park H.J., Lee S.-Y., Rho M.H., Jung H.L. Ultrasound and MRI findings as predictors of propranolol therapy response in patients with infantile hemangioma. PLoS One. 2021;16(3):e0247505. DOI: 10.1371/journal.pone.0247505.Park H.J., Lee S.-Y., Rho M.H., Jung H.L. Ultrasound and MRI findings as predictors of propranolol therapy response in patients with infantile hemangioma. PLoS One. 2021;16(3):e0247505. DOI: 10.1371/journal.pone.0247505.Chong J.H., Prey S., Mya H.T., Delarue A., Labreze C. Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol? British Journal of Dermatology. 2018;178(3):e196–e197. DOI: 10.1111/bjd.15966.Chong J.H., Prey S., Mya H.T., Delarue A., Labreze C. Can the extent of heart rate reduction predict the clinical response of infantile haemangiomas to propranolol? British Journal of Dermatology. 2018;178(3):e196–e197. DOI: 10.1111/bjd.15966.Yu L., Li S., Su B., Liu Z., Fang J., Zhu L. et al. Treatment of superficial infantile hemangiomas with timolol: evaluation of short-term efficacy and safety in infants. Experimental and Therapeutic Medicine. 2013;6(2):388–390.Yu L., Li S., Su B., Liu Z., Fang J., Zhu L. et al. Treatment of superficial infantile hemangiomas with timolol: evaluation of short-term efficacy and safety in infants. Experimental and Therapeutic Medicine. 2013;6(2):388–390.Wu H.W., Wang X., Zhang L., Zheng J.W., Liu C., Wang Y.A. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Frontiers in Oncology. 2018;8:605.Wu H.W., Wang X., Zhang L., Zheng J.W., Liu C., Wang Y.A. Topical timolol vs. oral propranolol for the treatment of superficial infantile hemangiomas. Frontiers in Oncology. 2018;8:605.Tani S., Kunimoto K., Inaba Y., Mikita N., Kaminaka C., Kanazawa N. et al. Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. Drug Discoveries & Therapeutics. 2020;14(2):89–92. DOI: 10.5582/ddt.2020.03014.Tani S., Kunimoto K., Inaba Y., Mikita N., Kaminaka C., Kanazawa N. et al. Change of serum cytokine profiles by propranolol treatment in patients with infantile hemangioma. Drug Discoveries & Therapeutics. 2020;14(2):89–92. DOI: 10.5582/ddt.2020.03014.Абдуллаев М.А., Кантемирова Б.И., Романова А.Н., Улуханов О.Б., Сеидова С.С. Анализ корреляции между уровнем сывороточного тромбоцитарного фактора роста и тяжестью острого коронарного синдрома. Современные проблемы науки и образования. 2024;(1).Абдуллаев М.А., Кантемирова Б.И., Романова А.Н., Улуханов О.Б., Сеидова С.С. Анализ корреляции между уровнем сывороточного тромбоцитарного фактора роста и тяжестью острого коронарного синдрома. Современные проблемы науки и образования. 2024;(1).Yamashita T., Jinnin M., Makino K., Kajihara I., Aoi J., Masuguchi S. et al. Serum cytokine profiles are altered in patients with progressive infantile hemangioma. Bioscience Trends. 2018;12(4):438–441. DOI: 10.5582/bst.2018.01118.Yamashita T., Jinnin M., Makino K., Kajihara I., Aoi J., Masuguchi S. et al. Serum cytokine profiles are altered in patients with progressive infantile hemangioma. Bioscience Trends. 2018;12(4):438–441. DOI: 10.5582/bst.2018.01118.El-Raggal N.M., El-Farrash R.A., Saad A.A., Attia E.A.S., Saafan H.A., Shaaban I.S. Circulating levels of vascular endothelial growth factor and basic fibroblastic growth factor in infantile hemangioma versus vascular malformations. Clinical and Applied Thrombosis/Hemostasis. 2018;24(4):663–668. DOI: 10.1177/1076029617710333.El-Raggal N.M., El-Farrash R.A., Saad A.A., Attia E.A.S., Saafan H.A., Shaaban I.S. Circulating levels of vascular endothelial growth factor and basic fibroblastic growth factor in infantile hemangioma versus vascular malformations. Clinical and Applied Thrombosis/Hemostasis. 2018;24(4):663–668. DOI: 10.1177/1076029617710333.

The authors declare that there are no conflicts of interest present.